Clinical trials: Steatosis of Liver
NASH, NASH - Nonalcoholic Steatohepatitis
Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD
The ENLIGHTEN study that will evaluate the efficacy of a novel DTx lifestyle intervention in participants with non-cirrhotic MASH.
- Conditions
- NASH, NASH - Nonalcoholic Steatohepatitis, Liver Diseases
- Trial name
- ENLIGHTEN (NCT06352177)
- Testing
- Noom Weight Application
- Sponsor
- Milton S. Hershey Medical Center
Healthy Diet, Fatty Liver
Metabolic Effects of Plant-based Diet
The purpose of this study is to assess the metabolic effects of plant based diet on healthy young adults.
- Conditions
- Healthy Diet, Fatty Liver, Insulin Resistance, Metabolic Syndrome
- Trial name
- NCT05351853
- Testing
- Omnivore, Vegetarian, Vegan
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Koç University
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
NAFLD Primary Care
Non-alcoholic fatty liver disease (NAFLD) is with 25% the most prevalent liver disorder in Western society and is associated with overweight, obesity, metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM), cardiovascular…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases, Type2 Diabetes, Metabolic Syndrome
- Trial name
- NCT04918732
- Testing
- FibroScan
- Where
- Netherlands
- Volunteers
- 1,470 people
- Sponsor
- Maastricht University
Colorectal Cancer, Steatohepatitis
A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
This multicenter randomized, placebo-controlled phase II study will enroll 132 first-line palliative treated subjects with metastatic KRAS wild type CRC.
- Trial name
- G-LUCAS (NCT01523639)
- Where
- 7 sites in Austria
- Volunteers
- 8 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Metabolic Disease, Obesity
Adiposity, Cardiometabolic and Neurocognitive Health Among Ethnic Groups: a Feasibility and Pilot Study
The goal of this pilot and feasibility study is to is to test the feasibility of conducting a cross-sectional study on adiposity and cardiometabolic and neurocognitive risk factors at Kings College Hospital NHS Foundation Trust…
- Conditions
- Metabolic Disease, Obesity, Hepatic Steato-Fibrosis, Cardiovascular Diseases
- Trial name
- ACNH (NCT06435611)
- Where
- 2 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- King's College Hospital NHS Trust
Anorexia Nervosa
Liver Biomarkers in Anorexia Nervosa
The main goal of the Liver Biomarkers in Anorexia Nervosa (LIBAN) study is to determine the prevalence of liver fibrosis in patient with Anorexia Nervosa.
- Trial name
- LIBAN (NCT05861375)
- Testing
- Fibroscan
- Where
- France
- Volunteers
- 43 people
- Sponsor
- Nantes University Hospital
Cirrhosis, Fatty Liver
A Pathophysiological Study of the Postprandial Human Liver (PLS)
Fatty liver disease is a globally widespread disease. The identification of valid biomarkers and targets for potential treatments requires in-depth knowledge about the pathophysiology of the postprandial liver.
- Trial name
- PLS (NCT03849235)
- Testing
- Standardised meal, Glucagon bolus
- Where
- Denmark
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Hvidovre
Non-Alcoholic Fatty Liver Disease
Effect of Dapagliflozin on Metabolic Parameters in Patients With Non-Alcoholic Fatty Liver Disease
This study was designed to assess the effect of dapagliflozin on body weight, blood sugar, liver enzymes, and blood fats in adults with non-alcoholic fatty liver disease (NAFLD), a condition involving excess fat accumulation in…
- Trial name
- NCT07881796
- Testing
- Dapagliflozin (10mg Tab)
- Where
- Pakistan
- Volunteers
- 146 people
- Sponsor
- Shalamar Hospital
Hepatic Steatosis, Overweight and Obesity
Implementation of the Fatty Liver Index in Primary Care
This trial aims to evaluate the impact on cardiovascular risk control in individuals in risk of being affected by hepatic steatosis through the implementation of a screening test (Fatty Liver Index) in Primary Care.
- Trial name
- FLI-AP (NCT06363617)
- Testing
- FLI
- Where
- Spain
- Volunteers
- 434 people
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, multinational, dose-finding study evaluating the efficacy of three treatment doses of CC-90001 compared with placebo, in Non-alcoholic Steatohepatitis…
- Trial name
- NCT04048876
- Testing
- CC-90001
- Where
- 142 sites in United States, Australia and 8 more
- Volunteers
- 56 people
- Sponsor
- Celgene
Fatty Liver, Nonalcoholic, Diet, Healthy
Nutritional Education Program for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Study Summary Title: Mediterranean Diet Intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (The TIMA Study) Introduction: This trial, known as the TIMA (Taiwanese…
- Trial name
- TIMA (NCT06503120)
- Testing
- Mediterranean-diet intervention group, Standard care
- Where
- Taiwan
- Volunteers
- 78 people
- Sponsor
- Taichung Veterans General Hospital
NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery
The purpose of this study is to evaluate imaging and other biomarkers of non-alcoholic fatty liver disease before and after bariatric surgery.
- Trial name
- BARI (NCT03294850)
- Testing
- Bariatric surgery, HepQuant SHUNT Dual Cholate Liver Diagnostic Kit
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Morbid Obesity, Steatosis
Very Low Calorie Liquid Diet for Pre op Patients
Despite the relative consensus on the benefits of pre-surgical weight loss, i.e., the reduction of comorbidities associated with surgical act, such as decreased visceral fat, liver volume, hemorrhage perioperative and surgical…
- Trial name
- NCT01748682
- Testing
- A very low calorie diet of two different consistencies
- Where
- Brazil
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Silvia Leite Faria
Non-alcoholic Fatty Liver Disease, Obesity
Magnetic Resonance Imaging (MRI) Fat Quantification of the Liver
Fatty liver in the obese is a common finding; some cases develop steato-hepatosis which in the long-term can lead to liver cirrhosis.
- Trial name
- NCT02682173
- Testing
- MR Abdomen
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- University Hospital, Basel, Switzerland
Type 2 Diabetes
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone…
- Trial name
- NCT06649162
- Where
- 2 sites in South Korea
- Volunteers
- 10,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 1 Diabetes, Liver Steatoses
Prevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes
The goal of this observational cross-sectional study is to assess the prevalence and stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), specifically liver steatosis and fibrosis in adults aged 18 and older…
- Conditions
- Type 1 Diabetes, Liver Steatoses, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
- Trial name
- STEA-DT1 (NCT07475962)
- Testing
- Adiposity and BMI Classification
- Volunteers
- 100 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
NASH
HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)
This study will evaluate the efficacy and safety and the best effective dose of HuHuangLianzonggan capsule in subjects with nonalcoholic steatohepatitis.
- Trial name
- NCT05632861
- Testing
- HuHuangLianzonggan capsule
- Where
- 20 sites in China
- Volunteers
- 76 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Obesity, Weight Loss
Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis
Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue.
- Conditions
- Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis
- Trial name
- NCT02933554
- Testing
- Embospheres Microspheres
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Keith Pereira, MD:
Nonalcoholic Steatohepatitis, Liver Cirrhosis
Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
This rollover study will provide open-label treatment with cenicriviroc and will assess the long-term safety of continued treatment with cenicriviroc in participants who participated in either the CENTAUR study 652-2-203…
- Conditions
- Nonalcoholic Steatohepatitis, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease
- Trial name
- NCT03059446
- Testing
- Cenicriviroc
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 167 people
- Sponsor
- Tobira Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.